There is an increasing interest in the therapeutic potential of ELF–PEMFs for patients with diseases associated with neovascularization.[27,40,41] It was previously reported that ELF–PEMFs negatively affect angiogenesis in breast cancer.[42] In addition, it was demonstrated that VEGFR2 expression and activation, which is an important factor in vascular formation by endothelial cells, decreased following ELF–PEMFs treatment.[26]. The gene discussed is KDR; the disease is breast carcinoma.